Sahir Kalim1, Guillermo Ortiz2, Caitlin A Trottier2, Joseph J Deferio2, S Ananth Karumanchi3, Ravi I Thadhani2, Anders H Berg4. 1. Division of Nephrology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: skalim@partners.org. 2. Division of Nephrology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 3. Division of Nephrology and Center for Vascular Biology Research, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. 4. Division of Clinical Chemistry, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Abstract
OBJECTIVE: Protein carbamylation is a urea-driven post-translational protein modification associated with mortality in dialysis patients. Free amino acids (AAs) are competitive inhibitors of protein carbamylation and animal studies suggest increasing AA concentrations reduces carbamylation burden. We hypothesized that AA therapy in maintenance hemodialysis patients would reduce carbamylation, carrying the potential to improve clinical outcomes. DESIGN: Prospective pilot clinical trial (NCT1612429). SETTING: The study was conducted from March 2013 to March 2014 in outpatient dialysis facilities in the Boston metropolitan area. SUBJECTS AND INTERVENTION: We enrolled 23 consecutively consenting hemodialysis subjects, infusing the first 12 individuals with 250 cc of AAs 3 times per week postdialysis over 8 weeks. The remaining 11 subjects served as controls. MAIN OUTCOME MEASURE: Change in carbamylated albumin (C-Alb), a measure of total body carbamylation burden, between baseline and 8 weeks was the primary outcome. RESULTS: The treated and control groups had similar clinical characteristics and similar baseline C-Alb levels (mean ± SE 9.5 ± 2.4 and 9.3 ± 1.3 mmol/mol, respectively; P = .61). The treated arm showed a significant reduction in C-Alb compared with controls at 4 weeks (8.4% reduction in the treated arm vs. 4.3% increase in controls; P = .03) and the effect was greater by 8 weeks (15% reduction in the treated vs. 1% decrease in controls; P = .01). CONCLUSION: In this pilot study, AA therapy appeared safe and effective at reducing C-Alb levels in hemodialysis patients compared with no treatment. The impact of reduced protein carbamylation on clinical outcomes should be further investigated.
OBJECTIVE: Protein carbamylation is a urea-driven post-translational protein modification associated with mortality in dialysis patients. Free amino acids (AAs) are competitive inhibitors of protein carbamylation and animal studies suggest increasing AA concentrations reduces carbamylation burden. We hypothesized that AA therapy in maintenance hemodialysis patients would reduce carbamylation, carrying the potential to improve clinical outcomes. DESIGN: Prospective pilot clinical trial (NCT1612429). SETTING: The study was conducted from March 2013 to March 2014 in outpatient dialysis facilities in the Boston metropolitan area. SUBJECTS AND INTERVENTION: We enrolled 23 consecutively consenting hemodialysis subjects, infusing the first 12 individuals with 250 cc of AAs 3 times per week postdialysis over 8 weeks. The remaining 11 subjects served as controls. MAIN OUTCOME MEASURE: Change in carbamylated albumin (C-Alb), a measure of total body carbamylation burden, between baseline and 8 weeks was the primary outcome. RESULTS: The treated and control groups had similar clinical characteristics and similar baseline C-Alb levels (mean ± SE 9.5 ± 2.4 and 9.3 ± 1.3 mmol/mol, respectively; P = .61). The treated arm showed a significant reduction in C-Alb compared with controls at 4 weeks (8.4% reduction in the treated arm vs. 4.3% increase in controls; P = .03) and the effect was greater by 8 weeks (15% reduction in the treated vs. 1% decrease in controls; P = .01). CONCLUSION: In this pilot study, AA therapy appeared safe and effective at reducing C-Alb levels in hemodialysis patients compared with no treatment. The impact of reduced protein carbamylation on clinical outcomes should be further investigated.
Authors: Robert A Koeth; Kamyar Kalantar-Zadeh; Zeneng Wang; Xiaoming Fu; W H Wilson Tang; Stanley L Hazen Journal: J Am Soc Nephrol Date: 2013-02-21 Impact factor: 10.121
Authors: W H Wilson Tang; Kevin Shrestha; Zeneng Wang; Allen G Borowski; Richard W Troughton; Allan L Klein; Stanley L Hazen Journal: J Card Fail Date: 2013-03-19 Impact factor: 5.712
Authors: Dominic S C Raj; Philip Zager; Vallbh O Shah; Elizabeth A Dominic; Oladipo Adeniyi; Pedro Blandon; Robert Wolfe; Arny Ferrando Journal: Am J Physiol Endocrinol Metab Date: 2003-09-16 Impact factor: 4.310
Authors: Sahir Kalim; Hector Tamez; Julia Wenger; Elizabeth Ankers; Caitlin A Trottier; Joseph J Deferio; Anders H Berg; S Ananth Karumanchi; Ravi I Thadhani Journal: Clin J Am Soc Nephrol Date: 2013-08-22 Impact factor: 8.237
Authors: Anders H Berg; Christiane Drechsler; Julia Wenger; Roberto Buccafusca; Tammy Hod; Sahir Kalim; Wenda Ramma; Samir M Parikh; Hanno Steen; David J Friedman; John Danziger; Christoph Wanner; Ravi Thadhani; S Ananth Karumanchi Journal: Sci Transl Med Date: 2013-03-06 Impact factor: 17.956
Authors: Jeffrey Perl; Sahir Kalim; Ron Wald; Marc B Goldstein; Andrew T Yan; Nazanin Noori; Mercedeh Kiaii; Julia Wenger; Christopher Chan; Ravi I Thadhani; S Ananth Karumanchi; Anders H Berg Journal: Hemodial Int Date: 2016-06-21 Impact factor: 1.812
Authors: Veronika Binder; Barbara Chruścicka-Smaga; Brith Bergum; Stéphane Jaisson; Philippe Gillery; Joar Sivertsen; Tor Hervig; Marta Kaminska; Ronak Tilvawala; Venkatesh V Nemmara; Paul R Thompson; Jan Potempa; Hans-Peter Marti; Piotr Mydel Journal: J Am Soc Nephrol Date: 2022-08-29 Impact factor: 14.978
Authors: Sahir Kalim; Caitlin A Trottier; Julia B Wenger; Josh Wibecan; Rayhnuma Ahmed; Elizabeth Ankers; S Ananth Karumanchi; Ravi Thadhani; Anders H Berg Journal: Clin J Am Soc Nephrol Date: 2016-07-21 Impact factor: 8.237